

INFORMATION DISCLOSURE STATEMENT


In compliance with the duty of disclosure under 37 C.F.R. §1.56, and in accordance with the practice under 37 C.F.R. §1.97, the Examiner's attention is directed to the documents listed on the enclosed Form PTO 1449. A copy of each of the listed documents is also enclosed. The filing of this Information Disclosure Statement should not be construed as an admission that any particular listed reference is effective prior art or discloses or renders obvious any aspect of the claimed invention.

This statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance. Please charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.


This Amendment and Information Disclosure Statement is being filed together with Petition for Extension of Time. In the event that these papers get separated, this constitutes a Petition for Extension of Time for the minimum period required to effect timely filing of this Amendment and Information Disclosure Statement, together with an authorization to charge any fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper to Deposit Account No. 19-2570.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicant
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\KLS\Cases\B2368C4\draft response 3-26-03.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. B2368C4	SERIAL NO. 08/458,033
		APPLICANT Hindley, et al.	
		FILING DATE June 1, 1995	GROUP 1626

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Black's Medical Dictionary, C.W.H. Havard, Eds., pp. 187-190 & 347 (1987). ✓
		The Textbook of Medicine, James B. Wyngaarden, Ed., pp. 1360-1381 (1988). ✓
		Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent," <i>Diabetes</i> 32(9), 804-810 (September 1983)
		Patent Certification Notice, July 11, 2003, Portions relating to U.S. 6,288,095
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.